Heron Therapeutics (HRTX) News Today $1.73 +0.01 (+0.58%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.72 -0.01 (-0.87%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Heron Therapeutics (HRTX) to Release Quarterly Earnings on ThursdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 21 at 2:21 AM | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Share Price Crosses Above 200-Day Moving Average - Time to Sell?February 15, 2025 | americanbankingnews.comHeron Therapeutics (NASDAQ:HRTX) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?Heron Therapeutics (NASDAQ:HRTX) Shares Cross Above 200 Day Moving Average - Should You Sell?February 15, 2025 | marketbeat.comHeron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025February 13, 2025 | prnewswire.comAccomplished CEO eyes another success story in CaryFebruary 13, 2025 | bizjournals.comHeron Therapeutics (NASDAQ:HRTX) Share Price Crosses Above 200 Day Moving Average - Here's What HappenedHeron Therapeutics (NASDAQ:HRTX) Share Price Passes Above Two Hundred Day Moving Average - Here's What HappenedFebruary 7, 2025 | marketbeat.comJPMorgan Chase & Co. Has $411,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)JPMorgan Chase & Co. boosted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 295.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 206,711 shares of the biotechnology company's stock after purchasingJanuary 30, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Stock Rating Lowered by StockNews.comStockNews.com lowered Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday.January 29, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) is a favorite amongst institutional investors who own 58%January 21, 2025 | finance.yahoo.comHeron Therapeutics (NASDAQ:HRTX) Upgraded to Buy at StockNews.comStockNews.com raised Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday.January 21, 2025 | marketbeat.comCongress Park Capital LLC Acquires 477,417 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)Congress Park Capital LLC lifted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 24.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,455,495 shares ofJanuary 17, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Downgraded to "Hold" Rating by StockNews.comStockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.January 13, 2025 | marketbeat.comFranklin Resources Inc. Sells 6,304,716 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)Franklin Resources Inc. lowered its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 99.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,026 shares of the biotechnology company's stoJanuary 3, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Sees Large Growth in Short InterestHeron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 29,980,000 shares, an increase of 8.9% from the November 30th total of 27,540,000 shares. Based on an average trading volume of 3,110,000 shares, the short-interest ratio is currently 9.6 days.January 1, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Rating Lowered to "Hold" at StockNews.comStockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday.December 31, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by State Street CorpState Street Corp decreased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 39.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,192,436 shares of the biotechnology company's stock after selling 2,088,December 29, 2024 | marketbeat.comCalifornia public company relocates to North CarolinaDecember 27, 2024 | bizjournals.comSan Diego Biotech Firm Heron Therapeutics Shifts Operations to North CarolinaDecember 27, 2024 | msn.comHeron Therapeutics relocates corporate headquarters to Cary, North CarolinaDecember 23, 2024 | markets.businessinsider.comHeron Therapeutics Announces Corporate Headquarters Relocation to Cary, North CarolinaDecember 23, 2024 | prnewswire.comHeron Therapeutics (NASDAQ:HRTX) Rating Increased to Buy at StockNews.comStockNews.com raised shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Wednesday.December 11, 2024 | marketbeat.comHeron Therapeutics Secures Revenue Stream with Court Ruling, Analyst Recommends BuyDecember 5, 2024 | markets.businessinsider.comHeron Therapeutics (NASDAQ:HRTX) Stock, Insider Trading ActivityDecember 5, 2024 | benzinga.comHeron Therapeutics patent victory removes ‘major overhang,’ says NorthlandDecember 5, 2024 | markets.businessinsider.comRelief For Heron Therapeutics After The Court Win On CinvantiDecember 4, 2024 | seekingalpha.comHeron Therapeutics’ patent of Cinvanti found valid by Delaware District CourtDecember 4, 2024 | markets.businessinsider.comU.S. District Court Upholds Validity of CINVANTI® PatentsDecember 3, 2024 | prnewswire.comHeron Therapeutics: Approved Therapy With Blockbuster Potential But Meager RevenuesNovember 30, 2024 | seekingalpha.comHeron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to "Hold"StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday.November 21, 2024 | marketbeat.comShort Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Declines By 6.0%Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 28,810,000 shares, a decline of 6.0% from the October 15th total of 30,640,000 shares. Based on an average daily volume of 1,830,000 shares, the days-to-cover ratio is currently 15.7 days.November 18, 2024 | marketbeat.comQ4 EPS Forecast for Heron Therapeutics Reduced by AnalystHeron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Research analysts at Northland Capmk cut their Q4 2024 earnings estimates for shares of Heron Therapeutics in a note issued to investors on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now expects that the biotechnology company wNovember 15, 2024 | marketbeat.comHeron Therapeutics: Anticipating Q4 Recovery and Legal Resolution Justifies Buy RatingNovember 14, 2024 | markets.businessinsider.comHeron Therapeutics (HRTX) Gets a Buy from Northland SecuritiesNovember 14, 2024 | markets.businessinsider.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comHeron Therapeutics (NASDAQ:HRTX) Given New $4.00 Price Target at Needham & Company LLCNeedham & Company LLC decreased their price objective on shares of Heron Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday.November 13, 2024 | marketbeat.comHeron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ...November 13, 2024 | finance.yahoo.comHeron Therapeutics narrows 2024 revenue view to $140M-$146M from $138M-$158MNovember 13, 2024 | markets.businessinsider.comHeron Therapeutics, Inc.: Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial GuidanceNovember 12, 2024 | finanznachrichten.deHeron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comHeron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial GuidanceNovember 12, 2024 | prnewswire.comHeron Therapeutics Strengthens Leadership with New Board AppointmentNovember 5, 2024 | markets.businessinsider.comPositive Signs As Multiple Insiders Buy Heron Therapeutics StockNovember 5, 2024 | finance.yahoo.comHeron Therapeutics (HRTX) Scheduled to Post Quarterly Earnings on TuesdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=641670)November 5, 2024 | marketbeat.comHeron Therapeutics Announces Appointment of Michael Kaseta to Board of DirectorsNovember 4, 2024 | prnewswire.comTop Performing High Short Interest StocksOctober 29, 2024 | benzinga.comHeron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024October 29, 2024 | prnewswire.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest UpdateHeron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the target of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 31,700,000 shares, a decline of 10.6% from the September 15th total of 35,440,000 shares. Based on an average daily volume of 2,200,000 shares, the short-interest ratio is currently 14.4 days.October 16, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Millennium Management LLCMillennium Management LLC lowered its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 54.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,434,627 shares of the biotechnology compaOctober 12, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Congress Park Capital LLCCongress Park Capital LLC raised its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 25.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,978,078 shares of the biotechnology company's stockOctober 11, 2024 | marketbeat.comHeron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous FluidsOctober 10, 2024 | prnewswire.com Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTX Media Mentions By Week HRTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HRTX News Sentiment▼0.530.60▲Average Medical News Sentiment HRTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HRTX Articles This Week▼32▲HRTX Articles Average Week Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Maravai LifeSciences News Today Enliven Therapeutics News Today Phibro Animal Health News Today Zymeworks News Today AbCellera Biologics News Today Replimune Group News Today Collegium Pharmaceutical News Today Rocket Pharmaceuticals News Today Evolus News Today Pharvaris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HRTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
